Detalle Publicación

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

Autores: Encinas, C.; Hernández-Rivas, J. A.; Oriol, A.; Rosinol, L.; Blanchard, M. J.; Bellón, J. M.; García-Sanz, R.; de la Rubia, J.; López de la Guía, A.; Jiménez-Ubieto, A.; Jarque, I.; Inigo, B.; Dourdil, V.; de Arriba, F.; Cuellar Pérez-Ávila, C.; González, Y.; Hernández, M. T.; Bargay, J.; Granell, M.; Rodríguez Otero, Paula; Silvent, M.; Cabrera, C.; Ríos, R.; Alegre, A.; Gironella, M.; González, M. S.; Sureda, A.; Sampol, A.; Ocio, E. M.; Krsnik, I.; García, A.; García-Mateo, A.; Soler, J. A.; Martín, J.; Arguiñano, J. M.; Mateos, M. V.; Blade, J.; San Miguel Izquierdo, Jesús; Lahuerta, J. J.; Martínez-López, J. (Autor de correspondencia)
Título de la revista: BLOOD CANCER JOURNAL
ISSN: 2044-5385
Volumen: 12
Número: 4
Páginas: 68
Fecha de publicación: 2022
Infections remain a common complication in patients with multiple myeloma (MM) and are associated with morbidity and mortality. A risk score to predict the probability of early severe infection could help to identify the patients that would benefit from preventive measures. We undertook a post hoc analysis of infections in four clinical trials from the Spanish Myeloma Group, involving a total of 1347 patients (847 transplant candidates). Regarding the GEM2010 > 65 trial, antibiotic prophylaxis was mandatory, so we excluded it from the final analysis. The incidence of severe infection episodes within the first 6 months was 13.8%, and majority of the patients experiencing the first episode before 4 months (11.1%). 1.2% of patients died because of infections within the first 6 months (1% before 4 months). Variables associated with increased risk of severe infection in the first 4 months included serum albumin <= 30 g/L, ECOG > 1, male sex, and non-IgA type MM. A simple risk score with these variables facilitated the identification of three risk groups with different probabilities of severe infection within the first 4 months: low-risk (score 0-2) 8.2%; intermediate-risk (score 3) 19.2%; and high-risk (score 4) 28.3%. Patients with intermediate/high risk could be candidates for prophylactic antibiotic therapies.